Albany Molecular Research, Inc. (AMRI) Stock Rating Upgraded by BidaskClub

Albany Molecular Research, Inc. (NASDAQ:AMRI) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday.

A number of other analysts have also issued reports on AMRI. J P Morgan Chase & Co lowered shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. William Blair lowered shares of Albany Molecular Research from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 6th. First Analysis lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. Finally, Morgan Stanley lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target for the company. in a research report on Thursday, May 11th. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating, Albany Molecular Research presently has an average rating of “Hold” and a consensus target price of $18.00.

Albany Molecular Research (AMRI) opened at 21.76 on Friday. Albany Molecular Research has a 12 month low of $13.01 and a 12 month high of $22.17. The firm’s market cap is $906.65 million. The firm’s 50-day moving average is $21.70 and its 200-day moving average is $18.08.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/08/13/albany-molecular-research-inc-amri-stock-rating-upgraded-by-bidaskclub.html.

Several hedge funds have recently bought and sold shares of AMRI. Municipal Employees Retirement System of Michigan raised its stake in Albany Molecular Research by 5.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock worth $114,000 after buying an additional 290 shares during the period. BNP Paribas Arbitrage SA raised its stake in Albany Molecular Research by 69.8% in the second quarter. BNP Paribas Arbitrage SA now owns 7,044 shares of the biotechnology company’s stock worth $153,000 after buying an additional 2,895 shares during the period. Round Table Services LLC bought a new stake in Albany Molecular Research during the second quarter worth about $205,000. ING Groep NV bought a new stake in Albany Molecular Research during the second quarter worth about $220,000. Finally, First Trust Advisors LP bought a new stake in Albany Molecular Research during the second quarter worth about $237,000. 73.43% of the stock is owned by institutional investors and hedge funds.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply